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Pseudohypoparathyroidism type 1A (PHP1A) is usually diagnosed in childhood or early adulthood. We describe the case of a 64-
year-old woman admitted to the Neurological Unit for recurrent episodes of loss of consciousness and seizures. Glycemia and
ECG were normal, while hypocalcemia was noted. Clinical history revealed carpo-pedal spasm since the age of 30 years, cognitive
impairment, hypothyroidism since early adulthood, and menopause at 30 years. She was taking oral calcium and cholecalciferol
for chronic hypocalcemia. Physical features suggested Albright’s osteodystrophy. Blood calcium was confirmed low, with increased
parathyroid hormone, moderate 25OH-vitamin D deficiency, and normal creatinine. Brain CT scan revealed calcifications of the
basal ganglia, cortical and subcortical white matter, and cerebellum. Therapy was switched to oral calcitriol, with normalization
of calcium levels; levetiracetam was started and no further seizures occurred. The clinical diagnosis of PHP1A was confirmed
by molecular analysis, which demonstrated the heterozygous c.568 571del mutation of the GNAS gene. Our report illustrates the
natural history of a patient with PHP1A, which went undiagnosed until the age of 64 years, with multi-hormonal resistance and
clinical sequelae evolving throughout life, and underlines the importance of diagnosing this rare disease, which has a great impact
on patients and their family life.
1. Introduction
Pseudohypoparathyroidism (PHP) is a rare congenital dis-
order, its estimated prevalence being 0.34 - 1.1 in 100.000; it
is characterized by impairment of the parathyroid hormone
(PTH) signaling pathway, with target organ resistance to the
action of PTH [1, 2]. The term PHP comprises several related
and highly heterogeneous diseases with genetic/epigenetic
causes [3, 4]. PTH exerts its actions by binding to a trans-
membrane G-protein-coupled receptor, activating cAMP
formation. The classical form of PHP, pseudohypoparathy-
roidism type 1A (PHP1A), which is associated with Albright’s
hereditary osteodystrophy (AHO), is caused by de novo
or autosomal dominantly inherited inactivating mutations
within the Gs𝛼-coding GNAS gene (20q13.3; OMIM #139320)
[5]. The maternal allele is the predominant source of Gs𝛼-
expression in the proximal renal tubule, thyroid, pituitary,
and gonads, since paternal Gs𝛼 expression is silenced in
these tissues; in other tissues, however, Gs𝛼 expression is
biallelic. Therefore, an inactivating Gs𝛼 mutation causes
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Figure 1: Basal ganglia (a) and subcortical (b) calcifications (CT scan).
PHP1A (AHO clinical features and hormone resistance) in
the case of maternal inheritance, while the same mutation
on the paternal allele results in AHO clinical features only,
a condition known as pseudo-pseudo-hypoparathyroidism
(PPHP).
PHP1A patients often develop target-organ resistance
to other hormones that act through Gs𝛼-coupled receptors,
particularly TSH; resistance to gonadotrophins and GHRH
is also reported.
The disease is usually diagnosed in childhood or early
adulthood age, and few studies have addressed its natural
history, in which its features evolve during the subject’s
lifetime.Moreover, to our knowledge, no diagnoses have been
made after 60 years of age in patients not studied for known
familial disease.
2. Clinical Case
A 64-year-old woman was admitted to the Neurological
Unit of our hospital for recent recurrent episodes of loss of
consciousness and seizures. Glycemia and ECGwere normal,
while hypocalcemia was present.
She has a normal brother and both her parents died in old
age; her mother had cognitive impairment. Her clinical his-
tory evidenced carpo-pedal spasm since the age of 30 years,
cognitive impairment, hypothyroidism diagnosed in early
adulthood, spontaneous menarche, and oligomenorrhea fol-
lowed by amenorrhea at the age of 30, which was diagnosed
as precocious menopause. She was unmarried and had no
pregnancy. She underwent bilateral hip arthroprosthesis at 45
and 50 years of age.
She was taking oral calcium (600mg daily) and cholecal-
ciferol (400 IU daily) for chronic hypocalcemia, diagnosed
about 30 years earlier. She was also on therapy with perindo-
pril for hypertension, atorvastatin for hypercholesterolemia,
and L-thyroxine.
Physical examination revealed short stature (145 cm),
slight overweight: 52Kg (BMI: 25Kg/m2), round facies,
enlarged base of the nose, and brachydactyly. Her blood
chemistry evidenced hypocalcemia (7.7mg/dl, n.v. 8.2-10.2)
with increased PTH levels (169 pg/ml, n.v. 15-65 pg/ml, intact
PTH immunoassay), moderate 25OH vitamin D deficiency
(22 ng/ml; n.v. ≥ 30), normal creatinine (1mg/dl), and albu-
min (3.9 g/dl).
Brain computed tomography (CT) revealed calcifications
of the basal ganglia, the cortical and subcortical white matter,
and the cerebellum (dentate nuclei); subcutaneous pericra-
nial ectopic calcifications were also present (Figures 1, 2, and
3). Hand radiography confirmed shortness of the metacarpal
bones and scapho-trapezoidal fusion (not shown). Bone
mineral density of the spine and femoral bone was normal.
Abdominal ultrasonography did not reveal kidney stones.
The clinical picture was suggestive of PHP1A. The patient
was therefore promptly switched to 1,25 (OH)
2
vitamin D
(calcitriol 0.75 mcg daily, in 3 split doses) associated with
oral calcium supplementation (1000mg daily in 2 split doses,
after lunch and dinner), with normalization of calcemia
(9.2mg/dl) and a decrease in PTH level (36 pg/ml). Serum
phosphate was normal on therapy (4.3mg/dl), while 24-hour
urinary calcium on therapy was above the normal range
(321mg/24 h, n.v. <4mg/kg/body weight); we do not have
a clear explanation for this, since urinary calcium excretion
is not normally increased in this condition. However, a
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Figure 2: Cerebellar calcifications (CT scan).
Figure 3: Extracranial subcutaneous ectopic calcifications (CT
scan).
laboratory assay pitfall or an incorrect urine collection by the
patient cannot be ruled out. A further urinary calciumcontrol
one month later, however, proved normal (200mg/24 h). In
addition, therapy with levetiracetam (1000mg daily in 2 split
doses) was started, and no further seizures or muscle spasms
occurred.
The patient and her family underwent a genetic counsel-
ing session and gave informed consent to genetic analysis.
Mutation analysis of the GNAS gene was performed on DNA
extracted from a blood sample by means of Sanger sequenc-
ing and MLPA according to standard methods. The analyses
revealed a heterozygous c.568 571del (p.Asp190Metfs∗13)
frameshift mutation. The combination of physical, biochem-
ical, and genetic findings led to the diagnosis of PHP1A.
FT4 and TSH levels were normal during substitu-
tive treatment with L-tiroxine (75 mcg daily). Anti-thy-
roperoxidase and anti-thyroglobulin antibodies were nega-
tive and thyroid ultrasonography was normal, suggesting that
TSH resistance was the cause of her hypothyroidism.
LH and FSH levels were in the menopausal range
(FSH: 47 mU/ml, LH: 26 mU/ml); the history of premature
menopause, however, was suggestive of the development of
progressive LH and FSH resistance. Prolactin, basal cortisol,
and ACTH levels were in the normal range. Basal growth
hormone was 0.63 ng/ml, with IGF-1 levels (129 ng/ml) in the
normal range for age. Calcitonin levels were increased (range:
44-92 pg/ml, n.v. <10 pg/ml) (she was not taking any proton-
pump inhibitor), while carcinoembryonic antigen (CEA) was
normal. Abdominal ultrasonography was normal, as were
chest-X-ray and mammography. Our interpretation is that
calcitonin resistance was also present, as part of the patient’s
multi-hormonal resistance due to impairment of the cAMP
activation pathway [6, 7].
Six months later, during follow-up evaluation, the
patient’s calcium level was seen to have increased to
10.6mg/dl and PTH had decreased to 32 pg/ml; oral calcium
supplementation was gradually reduced and then discon-
tinued, and calcitriol was reduced to 0.25 mcg twice daily;
subsequent controls revealed normal calcium (10mg/dl)
and slightly increased PTH (72 pg/ml) levels. She had no
further loss of consciousness or seizures; on neurological
examinations, levetiracetam treatment was confirmed, also
on account of the frailty of the patient.
3. Discussion
This is an unusual case of the first diagnosis of PHP type
1 A in a 64-year-old woman, who presented with hypocal-
cemia and recent recurrent episodes of loss of consciousness
and seizures. Combined evaluation of her clinical history,
physical features, blood chemistry, and radiological findings
suggested this diagnosis. A retrospective interpretation of
her history showed how the disease had evolved during
the patient’s lifetime: in early adulthood, she developed
PTH resistance-related hypocalcemia, carpo-pedal spasm,
and hypothyroidism due to TSH resistance; around the age
of 30 years, she suffered ovarian failure due to FSH and
LH resistance; this was followed by bilateral hip disease
requiring arthroprosthesis at 45 and 50 years and worsening
hypocalcemia, which was unresponsive to cholecalciferol
and oral calcium supplementation; finally, recurrent seizures
recently ensued. Calcitonin resistance was also present, while
IGF-1 was normal. She had no kidney stones; this is in
keeping with the observation that urinary calcium levels are
not markedly increased in these patients, as the action of
PTH is maintained in the distal renal tubule, where GNAS
gene expression is biallelic. Switching to calcitriol treatment
promptly corrected the woman’s hypocalcemia, and she had
neither muscle spasms nor seizures on anti-epileptic medi-
cation. Both hypocalcemia and the development of multiple
cortical and subcortical calcifications could have contributed
to the development of seizures.
Based on the patient’s clinical characterization, the tar-
geted mutation analysis of the GNAS gene identified a
known mutation already associated with PHP1A [8], thus
allowing the clinical diagnosis to be confirmed. The muta-
tion was presumably inherited from the mother, who was
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referred to as having cognitive impairment. However, as
no sample was available, this hypothesis was not formally
confirmed.
In accordance with the recommendations of the recently
published first consensus statement on the diagnosis and
management of pseudohypoparathyroidism-related disor-
ders [7], the diagnosis should be based on clinical and bio-
chemical characteristics, which will vary according to the age
of the patient. The diagnosis of AHO should be based on the
presence of major criteria (brachydactyly due to premature
fusion of the epiphyses and short stature by adulthood) and
additional criteria (stocky build, round facies, and ectopic
ossifications). Obesity, dental manifestations, and cognitive
impairment are present in a subgroup of patients. In the
majority of PHPpatients, themain clinical manifestations are
symptomsof hypocalcemia due to PTH resistance. In patients
with PHP1A, resistance to PTH is usually absent at birth and
evolves over time (from the neonatal period to 22 years);
the first biochemical abnormalities to appear are increased
serum PTH and phosphorous levels, whereas hypocalcemia
develops gradually 4-5 years later.Other associated endocrine
features that support the diagnosis are as follows: early-onset
hypothyroidism due to TSH resistance, which is the most
common associated endocrine alteration, being present in
nearly 100% of PHP1A patients; hypogonadism (due to FSH
and LH resistance); hypercalcitoninemia (due to calcitonin
resistance); GH deficiency (due to GHRH resistance).
Owing to the important implications for clinical manage-
ment, early screening for associated conditions and genetic
counselling, the molecular cause of PHP should be promptly
identified, in order to confirm the diagnosis and charac-
terize the subtype of the disease. Conversely, no genotype-
phenotype correlation can be inferred based on mutation
analysis [9]. In a large series, the recurrent c.568 571del
mutation detected in our patient was found associated with a
wide spectrum of phenotypical features. Namely, PTH levels
and serum calcium ranged from 57 to 653 pg/ml (reference
range 15-55) and from 1.3 to 2.7mmol/l (reference range 2.1-
2.6), respectively [10].
Few studies have focused on the natural history of this
disease and on the outcome of its management. The clinical
management of hypocalcemia in PHPpatients is based on the
administration of the active metabolite of vitamin D calcitriol
(1,25(OH)
2
vitamin D) as in the case of our patient, who was
previously on therapy with cholecalciferol.
Indeed, owing to PTH resistance, 25OHvitaminD cannot
be converted by the renal tubule into its biologically active
form, 1,25 (OH)
2
vitamin D, by PTH-dependent renal 1𝛼-
hydroxylase. The goal is to maintain normocalcemia and
to keep serum PTH levels in the upper portion of the
reference range, thereby avoiding PTH suppression, which
can be associated with hypercalciuria and renal calcification.
On the other hand, long-term and excessive secondary
hyperparathyroidism can result in osteitis fibrosa cystica
and dislocation of the femoral capital epiphysis (as may
have occurred in our patient, who underwent bilateral hip
replacement in adult age). PTH, calcium, and phosphorus
should be evaluated every six months during treatment in
asymptomatic patients, and more frequently when clinically
indicated. Patients and families should be instructed with
regard to the symptoms of hypo- and hypercalcemia.
The present case underlines the importance of early
diagnosis of pseudohypoparathyroidism, as this is crucial to
the appropriate treatment and lifelong management of the
disease and its complications, which have a great impact on
patients and their families. Appropriate genetic counselling
is essential in order to establish effective communication
with the family, which in turn allows relevant information
to be exchanged and genetic testing to be framed within an
integrated clinical path. This is in line with the recent con-
sensus statement [7], which recommends a multidisciplinary
approach addressing all aspects of the disease and its potential
complications.
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